A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)
Latest Information Update: 16 Jun 2025
At a glance
- Drugs Camlipixant (Primary)
- Indications Cough
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CALM-1
- Sponsors BELLUS Health
Most Recent Events
- 10 Jun 2025 Planned End Date changed from 1 Mar 2026 to 28 May 2026.
- 10 Jun 2025 Planned primary completion date changed from 1 Sep 2025 to 18 Dec 2025.
- 10 Jun 2025 Status changed from recruiting to active, no longer recruiting.